NCT03384238 2026-03-17
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Stanford University
Phase 1/2 Recruiting
Clinical Trials
12 trialsNCT03428958 2025-04-23
A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment
NuCana plc
Phase 1/2 Completed
NCT05121038 2024-12-17
CENDIFOX
University of Kansas Medical Center
Phase 1/2 Active not recruiting
NCT03263429 2024-08-30
Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer
Vanderbilt-Ingram Cancer Center
Phase 1/2 Completed
NCT00788957 2024-08-07
Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)
NantBioScience, Inc.
Phase 1/2 Completed
NCT01591421 2023-08-04
P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer.
Canadian Cancer Trials Group
Phase 1/2 Completed
NCT01504477 2020-03-16
Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer
Georgetown University
Phase 1/2 Terminated
NCT01128387 2019-12-09
Trial of Panitumumab/Cisplatin/Fluorouracil Combined With Radiation in Esophageal Cancer
University of Wisconsin, Madison
Phase 1/2 Terminated
NCT01139138 2017-11-06
PIE
The Queen Elizabeth Hospital
Phase 1/2 Completed
NCT01175733 2017-03-20
Vectibix
Amsterdam UMC, location VUmc
Phase 1/2 Completed
NCT00578071 2015-07-02
POXX
Duke University
Phase 1/2 Completed
NCT00630786 2014-02-06
Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study
Amgen
Phase 1/2 Completed